m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00156
 [1], [2], [3]
m6A modification ADAR1 ADAR1 METTL3 Methylation : m6A sites Direct Enhancement RNA modification ITGA2 ITGA2 ADAR Methylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Interferon-inducible protein 4 (ADAR1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target Integrin subunit alpha 2 (ITGA2) View Details
Crosstalk Relationship m6A  →  A-to-I Enhancement
Crosstalk Mechanism m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator
Crosstalk Summary METTL3 methylates Interferon-inducible protein 4 (ADAR1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADAR mediated A-to-I RNA editing of the Integrin subunit alpha 2 (ITGA2) transcript.
Responsed Drug E7820
 Drug Info 
Pathway Response mRNA surveillance pathway hsa03015
RNA degradation hsa03018
Cell Process RNA stability
In-vitro Model
 MGG8 Glioblastoma Homo sapiens CVCL_D1H4
U-87MG ATCC Glioblastoma Homo sapiens CVCL_0022
U-118MG Astrocytoma Homo sapiens CVCL_0633
HCCLM3 Adult hepatocellular carcinoma Homo sapiens CVCL_6832
SK-HEP-1 Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Integrin subunit alpha 2 (ITGA2) 5 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name E7820 Phase 2 [4]
Synonyms
289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 196970
TTD: D02BQE
DrugBank: DB12505
 Compound Name MAGGIEMYCIN Investigative [5]
Synonyms
81341-47-1; methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate; AC1Q6OOS; CTK3E8246; DTXSID70231061; AC1L3370; 1-naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester,(1r-trans)-; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester, (1R-trans)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 133657
TTD: D08PYJ
 Compound Name 3-(3-(carbamoyl)benzamido)propanoic acid Investigative [6]
Synonyms
CHEMBL219603
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418280
TTD: D01ZJF
 Compound Name 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid Investigative [6]
Synonyms
CHEMBL218226
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418282
TTD: D0G7QJ
 Compound Name 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid Investigative [6]
Synonyms
CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418281
TTD: D0TP8S
References
Ref 1 N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling. Genes (Basel). 2019 Feb 13;10(2):141. doi: 10.3390/genes10020141.
Ref 2 ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9.
Ref 3 ADAR1 p110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression. Med Sci Monit. 2019 Feb 24;25:1469-1479. doi: 10.12659/MSM.911944.
Ref 4 Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
Ref 5 Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. J Med Chem. 2007 May 31;50(11):2742-6.
Ref 6 Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. doi: 10.1016/j.bmcl.2006.07.090. Epub 2006 Aug 21.